KRAS and colon carcinoma: This differential impact of MEK1 and MEK2 on cell proliferation was observed in three different colon carcinoma cell lines (bearing activating mutations in either KRAS or BRAF), as well as in the breast adenocarcinoma cell line MDA-MB-231.